FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma
The US Food and Drug Administration (FDA) announced this week an indication extension approval for...
MSD
Merck Sharp & Dohme Launches Recarbrio in China for Bacterial Pneumonia and Infections
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the official...
Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of...
Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech
Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...
MSD’s Gardasil 9 Approved in China for Males Aged 16 to 26
US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced marketing approval from...
Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the European Commission (EC)...
Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...
BioCity and MSD Enter Clinical Collaboration for BC3195 and Keytruda Combination Trial
China-based BioCity Biopharmaceutics Co., Ltd. announced a clinical collaboration agreement with US-based giant Merck, Sharp...
Merck Sharp & Dohme Expands Durham Facility with $1B Investment for Vaccine Production
US-based giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the opening of a...
MSD China Reorganizes to Boost Mature Product Lines
Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and...
Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer
China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...
Merck’s Keytruda sBLA for LA-HNSCC Accepted by FDA for Review
Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that the US Food and Drug...
Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens
UK-based RNA immunotherapy developer Epitopea announced a licensing and research cooperation agreement with US pharmaceutical...
Merck’s Welireg Wins Conditional EU Approval for VHL Disease and Advanced RCC
US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that it has received...
Merck’s Zerbaxa Approved by China’s NMPA for Complex Infections
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced that it has...
Merck Initiates Phase III waveLINE-010 Study for Zilovertamab Vedotin in DLBCL
US-based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of...
MSD Reports Strong Global Sales Growth in 2024, Despite China Challenges
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) released its Q4 2024 financial report,...
Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...
MSD and Eisai’s Keytruda/Lenvima Combo Shows Promise in Gastroesophageal Cancer Study
Partners Merck, Sharp & Dohme (MSD, NYSE: MRK) and Eisai (TYO: 4523) have announced the...
Merck’s Keytruda Gains NMPA Approval for HNSCC Indication in China
US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) has announced that it has received...